These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32847720)

  • 1. Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins.
    Liu X; Feng D; Zheng M; Cui Y; Zhong D
    Drug Metab Pharmacokinet; 2020 Oct; 35(5):456-465. PubMed ID: 32847720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein.
    Meng J; Liu XY; Ma S; Zhang H; Yu SD; Zhang YF; Chen MX; Zhu XY; Liu Y; Yi L; Ding XL; Chen XY; Miao LY; Zhong DF
    Acta Pharmacol Sin; 2019 Jul; 40(7):980-988. PubMed ID: 30382184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ.
    Fournier JCL; Evans JP; Zappacosta F; Thomas DA; Patel VK; White GV; Campos S; Tomkinson NCO
    ACS Chem Biol; 2021 Sep; 16(9):1644-1653. PubMed ID: 34397208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.
    Dömötör O; Pelivan K; Borics A; Keppler BK; Kowol CR; Enyedy ÉA
    J Pharm Biomed Anal; 2018 May; 154():321-331. PubMed ID: 29567575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib.
    Wang Z; Yong Chan EC
    Drug Metab Dispos; 2022 Oct; 50(10):1332-1341. PubMed ID: 35817438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible covalent binding of neratinib to human serum albumin in vitro.
    Chandrasekaran A; Shen L; Lockhead S; Oganesian A; Wang J; Scatina J
    Drug Metab Lett; 2010 Dec; 4(4):220-7. PubMed ID: 20690900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin.
    Wu Y; Chen L; Chen J; Xue H; He Q; Zhong D; Diao X
    Drug Metab Dispos; 2023 Jan; 51(1):8-16. PubMed ID: 36328480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of a tyrosine kinase inhibitor, vandetanib with human serum albumin as studied by fluorescence quenching and molecular docking.
    Kabir MZ; Feroz SR; Mukarram AK; Alias Z; Mohamad SB; Tayyab S
    J Biomol Struct Dyn; 2016 Aug; 34(8):1693-704. PubMed ID: 26331959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of Janus kinase inhibitor tofacitinib with human serum albumin: multi-technique approach.
    Abdelhameed AS; Alam P; Khan RH
    J Biomol Struct Dyn; 2016 Sep; 34(9):2037-44. PubMed ID: 26440737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BTK-inhibitor drug covalent binding to lysine in human serum albumin using LC-MS/MS.
    Muste C; Gu C
    Drug Metab Pharmacokinet; 2022 Feb; 42():100433. PubMed ID: 34896750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.
    Tinworth CP; Lithgow H; Dittus L; Bassi ZI; Hughes SE; Muelbaier M; Dai H; Smith IED; Kerr WJ; Burley GA; Bantscheff M; Harling JD
    ACS Chem Biol; 2019 Mar; 14(3):342-347. PubMed ID: 30807093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectroscopic methodologies and molecular docking studies on the interaction of antimalarial drug piperaquine and its metabolites with human serum albumin.
    Ma R; Guo DX; Li HF; Liu HX; Zhang YR; Ji JB; Xing J; Wang SQ
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Nov; 222():117158. PubMed ID: 31181505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
    Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
    J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies.
    Zhai X; Ward RA; Doig P; Argyrou A
    Biochemistry; 2020 Apr; 59(14):1428-1441. PubMed ID: 32207968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of interactions between human serum albumin and niraparib through multi-spectroscopic and computational methods.
    Gan N; Sun Q; Tang P; Wu D; Xie T; Zhang Y; Li H
    Spectrochim Acta A Mol Biomol Spectrosc; 2019 Jan; 206():126-134. PubMed ID: 30096696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the binding of quinoline amines with human serum albumin by spectroscopic and induced fit docking methods.
    Vennila KN; Elango KP
    J Biomol Struct Dyn; 2019 Jul; 37(11):2753-2765. PubMed ID: 30052140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
    Dickinson PA; Cantarini MV; Collier J; Frewer P; Martin S; Pickup K; Ballard P
    Drug Metab Dispos; 2016 Aug; 44(8):1201-12. PubMed ID: 27226351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
    Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
    J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the binding of a novel antitumor drug ibrutinib with human serum albumin: Insights from spectroscopic, calorimetric and docking studies.
    Tang B; Tang P; He J; Yang H; Li H
    J Photochem Photobiol B; 2018 Jul; 184():18-26. PubMed ID: 29777941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectroscopic methodologies and molecular docking studies on the interaction of the soluble guanylate cyclase stimulator riociguat with human serum albumin.
    Ma R; Li Z; Di X; Guo D; Ji J; Wang S
    Biosci Trends; 2018 Sep; 12(4):369-374. PubMed ID: 30101825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.